BNP Paribas Financial Markets’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.54K | Buy |
1,426
+167
| +13% | +$654 | ﹤0.01% | 5327 |
|
|
2025
Q4 | $5.41K | Buy |
1,259
+125
| +11% | +$1.12K | ﹤0.01% | 5249 |
|
|
2025
Q3 | $44.2K | Buy |
1,134
+834
| +278% | +$23.7K | ﹤0.01% | 4647 |
|
|
2025
Q2 | $7K | Buy |
300
+288
| +2,400% | +$6.81K | ﹤0.01% | 4916 |
|
|
2025
Q1 | $177 | Sell |
12
-4,445
| -100% | -$67.1K | ﹤0.01% | 5221 |
|
|
2024
Q4 | $81.8K | Sell |
4,457
-11,725
| -72% | -$128K | ﹤0.01% | 4234 |
|
|
2024
Q3 | $179K | Sell |
16,182
-13,729
| -46% | -$161K | ﹤0.01% | 3288 |
|
|
2024
Q2 | $278K | Buy |
29,911
+21,961
| +276% | +$524K | ﹤0.01% | 2967 |
|
|
2024
Q1 | $260K | Sell |
7,950
-185
| -2% | -$4.8K | ﹤0.01% | 3165 |
|
|
2023
Q4 | $218K | Buy |
8,135
+6,273
| +337% | +$260K | ﹤0.01% | 3178 |
|
|
2023
Q3 | $113K | Sell |
1,862
-294
| -14% | -$27.6K | ﹤0.01% | 3297 |
|
|
2023
Q2 | $220K | Buy |
2,156
+419
| +24% | +$57.7K | ﹤0.01% | 2979 |
|
|
2023
Q1 | $307K | Buy |
1,737
+1,373
| +377% | +$460K | ﹤0.01% | 2972 |
|
|
2022
Q4 | $141K | Sell |
364
-614
| -63% | -$233K | ﹤0.01% | 3127 |
|
|
2022
Q3 | $330K | Buy |
978
+346
| +55% | +$125K | ﹤0.01% | 3248 |
|
|
2022
Q2 | $208K | Sell |
632
-288
| -31% | -$101K | ﹤0.01% | 3070 |
|
|
2022
Q1 | $403K | Sell |
920
-89
| -9% | -$36.5K | ﹤0.01% | 2864 |
|
|
2021
Q4 | $442K | Sell |
1,009
-533
| -35% | -$268K | ﹤0.01% | 3065 |
|
|
2021
Q3 | $858K | Buy |
1,542
+667
| +76% | +$335K | ﹤0.01% | 2469 |
|
|
2021
Q2 | $450K | Buy |
875
+420
| +92% | +$266K | ﹤0.01% | 2579 |
|
|
2021
Q1 | $355K | Buy |
455
+96
| +27% | +$65.7K | ﹤0.01% | 2762 |
|
|
2020
Q4 | $196K | Buy |
359
+93
| +35% | +$48.7K | ﹤0.01% | 2890 |
|
|
2020
Q3 | $122K | Buy |
266
+225
| +549% | +$131K | ﹤0.01% | 3006 |
|
|
2020
Q2 | $25.2K | Sell |
41
-303
| -88% | -$167K | ﹤0.01% | 3292 |
|
|
2020
Q1 | $164K | Buy |
344
+213
| +163% | +$116K | ﹤0.01% | 2962 |
|
|
2019
Q4 | $75.9K | Sell |
131
-34
| -21% | -$23.9K | ﹤0.01% | 3426 |
|
|
2019
Q3 | $109K | Buy |
165
+64
| +63% | +$53.2K | ﹤0.01% | 3082 |
|
|
2019
Q2 | $78.2K | Sell |
101
-87
| -46% | -$61.1K | ﹤0.01% | 3170 |
|
|
2019
Q1 | $133K | Buy |
+188
| New | +$113K | ﹤0.01% | 2951 |
|
|
2018
Q4 | – | Sell |
-25
| Closed | -$16.1K | – | 4153 |
|
|
2018
Q3 | $21.1K | Sell |
25
-2
| -7% | -$1.44K | ﹤0.01% | 3395 |
|
|
2018
Q2 | $18.5K | Sell |
27
-131
| -83% | -$66.6K | ﹤0.01% | 3526 |
|
|
2018
Q1 | $70.5K | Buy |
158
+5
| +3% | +$2.42K | ﹤0.01% | 3371 |
|
|
2017
Q4 | $67.3K | Buy |
153
+89
| +139% | +$40.6K | ﹤0.01% | 3514 |
|
|
2017
Q3 | $31.4K | Sell |
64
-4
| -6% | -$2K | ﹤0.01% | 3378 |
|
|
2017
Q2 | $37.7K | Buy |
68
+67
| +6,700% | +$42.5K | ﹤0.01% | 3339 |
|
|
2017
Q1 | $405 | Sell |
1
-3
| -75% | -$1.6K | ﹤0.01% | 3879 |
|
|
2016
Q4 | $1.48K | Sell |
4
-35
| -90% | -$11.2K | ﹤0.01% | 3974 |
|
|
2016
Q3 | $11.6K | Buy |
39
+17
| +77% | +$3.68K | ﹤0.01% | 3126 |
|
|
2016
Q2 | $3.79K | Buy |
+22
| New | +$4.79K | ﹤0.01% | 3367 |
|
|
2016
Q1 | – | Sell |
-107
| Closed | -$64.7K | – | 3113 |
|
|
2015
Q4 | $64.7K | Sell |
107
-4
| -4% | -$2.2K | ﹤0.01% | 2615 |
|
|
2015
Q3 | $57.1K | Buy |
111
+72
| +185% | +$48.2K | ﹤0.01% | 2766 |
|
|
2015
Q2 | $16.9K | Buy |
39
+35
| +875% | +$13.5K | ﹤0.01% | 3152 |
|
|
2015
Q1 | $1.34K | Buy |
+4
| New | +$1.51K | ﹤0.01% | 3531 |
|
|
2014
Q4 | – | Sell |
-3
| Closed | -$998 | – | 3294 |
|
|
2014
Q3 | $998 | Sell |
3
-5
| -63% | -$2.05K | ﹤0.01% | 3998 |
|
|
2014
Q2 | $5.04K | Buy |
+8
| New | +$4.31K | ﹤0.01% | 2582 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
BNP Paribas Financial Markets's TVRD Position: Q1 2026 in Review
BNP Paribas Financial Markets increased its Tvardi Therapeutics (TVRD) stake by 13% in Q1 2026, buying an estimated $654 and bringing the position to 1,426 shares worth $4.54K. The position accounts for ﹤0.01% of the portfolio, ranked #5327.
BNP Paribas Financial Markets first reported a position in TVRD in Q2 2014 and has held it in 45 quarters since. The position peaked at $858K in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- BNP Paribas Financial Markets held 1,426 shares of Tvardi Therapeutics worth $4.54K as of Q1 2026.
- BNP Paribas Financial Markets bought 167 Tvardi Therapeutics shares in Q1 2026, an estimated $654.
- Tvardi Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5327 holding.
- BNP Paribas Financial Markets first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 45 quarters since.
- BNP Paribas Financial Markets's Tvardi Therapeutics position peaked at $858K in Q3 2021.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.